Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 30:2:1284740.
doi: 10.3389/frtra.2023.1284740. eCollection 2023.

Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies

Stephanie Ji  1 , Hao Liu  2 , Laura Pachella  3 , Ryan D Stephenson  3 , Roman Groisberg  3 , Sarah A Weiss  3
Affiliations

Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies

Stephanie Ji et al. Front Transplant. .

Abstract

Background: Immune checkpoint inhibitors (ICI) are standard of care therapy for patients with cutaneous malignancies, the most frequently diagnosed cancers in solid organ transplant (SOT) recipients. The activity and rate of allograft rejection in SOT recipients with advanced skin cancers treated with ICI is understudied.

Methods: We conducted a retrospective analysis of SOT recipients with advanced melanoma, cutaneous squamous cell carcinoma (cSCC), and merkel cell carcinoma (MCC) who were treated with ICI. Unpublished cases from our institution and published cases from the literature were aggregated. Demographics, type of immunosuppressive therapy, type of ICI(s) administered, prior systemic therapies, tumor response to ICI, and evidence of organ rejection and/or failure were recorded. Objective response rates (ORR) and rates of graft rejection and failure are reported.

Results: Ninety patients were identified; four patients from our institution and 86 unique patients from a literature review. ORR to first-line ICI for the entire cohort was 41.1% (37/90). ORR by tumor type was 31% (18/58), 64.3% (18/28), and 25.0% (1/4) for melanoma, cSCC, and MCC, respectively. The rate of graft rejection was 37.8% (34/90) with 61.8% (21/34) of these cases progressing to graft failure. Number of immunosuppressive agents (0, 1, 2, or 3) was inversely associated with rate of graft failure.

Conclusions: In this retrospective analysis, ICIs demonstrate clinical activity in SOT recipients with cutaneous malignancies; however, the rate of graft rejection is high. Treatment plans should be individualized through thorough interdisciplinary discussion. Immunosuppressive modifications may be considered prior to starting treatment, but when feasible, enrollment on clinical trials is preferred.

Keywords: cutaneous squamous cell carcinoma; immune checkpoint inhibitor; melanoma; merkel cell carcinoma; solid organ transplant.

PubMed Disclaimer

Conflict of interest statement

SW has consulted for Lyell Immunopharma and Incyte. RG is an employee of Merck. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Similar articles

See all similar articles

Cited by

References

    1. https://unos.org/news/2022-organ-transplants-again-set-annual-records/ 2022 organ transplants again set annual records. United Network for Organ Sharing (2023). Available at:
    1. Neergaard L. US counts millionth organ transplant while pushing for more. New York: Associated Press News. (2022). Available at: https://apnews.com/article/science-health-organ-transplants-government-a...
    1. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. (2000) 23(2):101–13. 10.2165/00002018-200023020-00002 - DOI - PubMed
    1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. (2007) 370(9581):59–67. 10.1016/S0140-6736(07)61050-2 - DOI - PubMed
    1. Engels EA, Pfeiffer RM, Fraumeni JF, Jr., Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. (2011) 306(17):1891–901. 10.1001/jama.2011.1592 - DOI - PMC - PubMed

LinkOut - more resources